OBJECTIVE: Matrix metalloproteinases (MMPs) form a large family of enzymes that collectively can degrade all components of the extracellular matrix, and there is widespread interest in developing MMP inhibitors for the prevention of atherosclerotic plaque rupture. We have therefore investigated the effects of a broad-spectrum MMP inhibitor, RS-130830, on plaque development and stability. This compound inhibits a wide range of MMPs at concentrations below 20 nmol/L. METHODS: Apolipoprotein E knockout mice were fed a Western diet. Dietary administration of RS-130830 commenced at the same time as fat-feeding and continued for 8, 12, 26 or 36 weeks. To investigate the effect of RS-130830 on established plaques, mice were fed high-fat diet for 16 weeks before initiation of drug treatment and were terminated 20 weeks after this. RESULTS: Broad-spectrum MMP inhibition was associated with a significant increase in plaque area, but there was no change in the incidence of plaque rupture. There were unfavourable changes in phenotypic characteristics associated with plaque instability, such as an increased lipid content and decreased collagen content. CONCLUSIONS: These data suggest that broad-spectrum MMP inhibition RS-130830 does not have a beneficial effect on atherosclerosis in the apolipoprotein E knockout mouse model, and indicate that more selective compounds would be preferable.
OBJECTIVE: Matrix metalloproteinases (MMPs) form a large family of enzymes that collectively can degrade all components of the extracellular matrix, and there is widespread interest in developing MMP inhibitors for the prevention of atherosclerotic plaque rupture. We have therefore investigated the effects of a broad-spectrum MMP inhibitor, RS-130830, on plaque development and stability. This compound inhibits a wide range of MMPs at concentrations below 20 nmol/L. METHODS:Apolipoprotein E knockout mice were fed a Western diet. Dietary administration of RS-130830 commenced at the same time as fat-feeding and continued for 8, 12, 26 or 36 weeks. To investigate the effect of RS-130830 on established plaques, mice were fed high-fat diet for 16 weeks before initiation of drug treatment and were terminated 20 weeks after this. RESULTS: Broad-spectrum MMP inhibition was associated with a significant increase in plaque area, but there was no change in the incidence of plaque rupture. There were unfavourable changes in phenotypic characteristics associated with plaque instability, such as an increased lipid content and decreased collagen content. CONCLUSIONS: These data suggest that broad-spectrum MMP inhibition RS-130830 does not have a beneficial effect on atherosclerosis in the apolipoprotein E knockout mouse model, and indicate that more selective compounds would be preferable.
Authors: György Dormán; Sándor Cseh; István Hajdú; László Barna; Dénes Kónya; Krisztina Kupai; László Kovács; Péter Ferdinandy Journal: Drugs Date: 2010-05-28 Impact factor: 9.546
Authors: Yan Zhao; Yuji Kuge; Songji Zhao; Koichi Morita; Masayuki Inubushi; H William Strauss; Francis G Blankenberg; Nagara Tamaki Journal: Eur J Nucl Med Mol Imaging Date: 2007-04-17 Impact factor: 9.236
Authors: Jie Hong Hu; Phanith Touch; Jingwan Zhang; Hao Wei; Shihui Liu; Ida K Lund; Gunilla Høyer-Hansen; David A Dichek Journal: Cardiovasc Res Date: 2015-01-23 Impact factor: 10.787
Authors: Andrew C Newby; Sarah J George; Yasmin Ismail; Jason L Johnson; Graciela B Sala-Newby; Anita C Thomas Journal: Thromb Haemost Date: 2009-06 Impact factor: 5.249
Authors: Jason L Johnson; Laurent Devel; Bertrand Czarny; Sarah J George; Christopher L Jackson; Vassilis Rogakos; Fabrice Beau; Athanasios Yiotakis; Andrew C Newby; Vincent Dive Journal: Arterioscler Thromb Vasc Biol Date: 2011-01-06 Impact factor: 8.311